Mericitabine (RG7128), an orally administered prodrug of PSI-6130, is the most clinically advanced nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV. This review describes what has been learnt so far about the resistance profile of mericitabine. A serine to threonine substitution at position 282 (S282T) of the RdRp that reduces its replication capacity to approximately 15% of wild-type is the only variant that has been consistently generated in serial in vitro passage experiments. To date, no evidence of genotypic resistance to mericitabine has been detected by population or clonal sequence analysis in any baseline or on-treatment samples collected from >600 patients enrolled in Phase I/II trials of mericitabine administered as monotherapy, in combination with pegylated interferon/ ribavirin, or in combination with the protease inhibitor, danoprevir, for 14 days in the proof-of-concept study of interferon-free therapy.
McHutchisonJ.G., EversonG.T., GordonS.C.Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med2009; 360: 1827–1838.
4.
HézodeC., ForestierN., DusheikoG.Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med2009; 360: 1839–1850.
5.
KwoP.Y., LawitzE.J., McConeJ.Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre Phase 2 trial. Lancet2010; 376: 705–716.
6.
McHutchisonJ.G., MannsM.P., MuirA.J.Telaprevir for previously treated chronic HCV infection. N Engl J Med2010; 362: 1292–1303.
7.
BaconB.R., GordonS.C., LawitzE.Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med2011; 364: 1207–1217.
8.
PoordadF., McConeJ.Jr., BaconB.R.Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med2011; 364: 1195–1206.
9.
JacobsonI.M., McHutchisonJ.G., DusheikoG.Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med2011; 364: 2405–2416.
10.
ZeuzemS., AndreoneP., PolS.Telaprevir for retreatment of HCV infection. N Engl J Med2011; 364: 2417–2428.
11.
SarrazinC., KiefferT.L., BartelsD.Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology2007; 132: 1767–1777.
12.
SarrazinC., RouzierR., WagnerF.SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology2007; 132: 1270–1278.
13.
KiefferT.L., SarrazinC., MillerJ.S.Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology2007; 46: 631–639.
14.
ChevaliezS., RodriguezA., SoulierA., Ahmed-BelkacemA., HézodeC., PawlotskyJ-M. Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: preexisting resistant variants and dynamics of resistant populations. J Hepatol2011; 54Suppl 1: S30.
15.
PawlotskyJ.M.Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology2011; 53: 1742–1751.
16.
Incivek (telaprevir).Package insert2011. Vertex Pharmaceuticals, Inc., Cambridge, MA, USA.
17.
Victrelis (Boceprevir).Package insert2011. Schering Corporation, a subsidiary of Merck and Co., Whitehouse Station, NJ, USA.
18.
ZeuzemS., SulkowskiM., ZoulimF.Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EXTEND study. Hepatology2010; 52Suppl 1: 436A.
19.
SullivanJ., De MeyerS., BartelsD.Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. J Hepatol2011; 54Suppl 1: S4.
20.
ZeiselM.B., FofanaI., Faf-KremerS., BaumertT.F.Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol2011; 54: 566–576.
21.
AshfaqU.A., JavedT., RehmanS., NawazZ., RiazuddinS.An overview of HCV molecular biology, replication and immune responses. Virol J2011; 8: 161.
22.
PawlotskyJ.M., ChevaliezS., McHutchisonJ.G.The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology2007; 132: 1979–1998.
23.
HalfonP., LocarniniS.Hepatitis C virus resistance to protease inhibitors. J Hepatol2011; 55: 192–206.
24.
VermehrenJ., SarrazinC.New HCV therapies on the horizon. Clin Microbiol Infect2011; 17: 122–134.
25.
ReesinkH.W., ZeuzemS., WeeginkC.J.Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology2006; 131: 997–1002.
26.
Le PogamS., YanJ., ChhabraM.Low prevalence of danoprevir resistance identified in genotype 1b HCV patients with prior null response treated with danoprevir plus low-dose ritonavir plus peginterferon alfa-2a (40KD)/ribavirin for 12 weeks. J Hepatol2011; 54Suppl 1: S485.
27.
McCownM.F., RajyaguruS., KularS., CammackN., NajeraI.GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother2009; 53: 2129–2132.
28.
SarrazinC., ZeuzemS.Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology2010; 138: 447–462.
29.
WagnerF., ThompsonR., KantaridisC.Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Hepatology2011; 54: 50–59.
30.
LokA., GardinerD., LawitzE.Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders. J Hepatol2011; 54Suppl 1: S536.
31.
ZeuzemS., BuggischP., AgarwalK.Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PEGIFN/ RBV for up to 28 days in treatment naive genotype 1 HCV subjects. Hepatology2010; 52Suppl 1: 400A.
32.
CoelmontL., HanoulleX., ChatterjiU.DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS ONE2010; 5: e13687.
33.
PuyangX., PoulinD.L., MathyJ.E.Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors. Antimicrob Agents Chemother2010; 54: 1981–1987.
34.
McCownM.F., RajyaguruS., Le PogamS.The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother2008; 52: 1604–1612.
35.
LamA.M., EspirituC., BansalS.Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations with replicon RNA. J Virol2011; 85: 12334–12342.
36.
LawitzE., Rodriguez-TorresM., DenningJ.Once daily dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV RNA < LOD at day 14: first purine/pyrimidine clinical combination data (the NUCLEAR study). J Hepatol2011; 54Suppl 1: S543.
37.
MaH., JiangW.R., RobledoN.Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-d-2′-Deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and identification of a novel active 5′-triphosphate species. J Biol Chem2007; 282: 29812–29820.
38.
MurakamiE., BaoH., RameshM.Mechanism of activation of beta- d-2′-deoxy-2′-fluoro-2′-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob Agents Chemother2007; 51: 503–509.
39.
MurakamiE., NiuC., BaoH.The mechanism of action of beta- d-2′-deoxy-2′-fluoro-2′-C-methylcytidine involves a second metabolic pathway leading to beta-d-2′-deoxy-2′-fluoro-2′-C-methyluridine 5′-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother2008; 52: 458–464.
40.
LevequeV., FungA., Le PogamS.Nucleoside analog R7128, a prodrug of PSI-6130, shows inhibition potency across HCV genotypes 1–6 in vitro.16th International Symposium on Hepatitis C Virus and Related Viruses. 3–7 October 2009, Nice, France. Poster P-215.
41.
AliS., LevequeV., Le PogamS.Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob Agents Chemother2008; 52: 4356–4369.
42.
MigliaccioG., TomassiniJ.E., CarrollS.S.Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem2003; 278: 49164–49170.
43.
OlsenD.B., EldrupA.B., BartholomewL.A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob Agents Chemother2004; 48: 3944–3953.
44.
Le PogamS., JiangW.R., LevequeV.In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology2006; 351: 349–359.
45.
ReddyR., Rodriguez-TorresM., GaneE.Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology2007; 46Suppl 1: 862A–863A.
46.
GaneE., Rodriguez-TorresM., NelsonD.Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: interim results of R7128 1500mg BID with PEG-IFN and ribavirin for 28 days. Hepatology2008; 48Suppl 1: 1024A.
47.
Rodriguez-TorresM., LalezariJ., GaneE.Potent antiviral response to the HCV nucleoside polymerase inhibitor R7128 for 28 days with PEG-IFN and ribavirin: subanalysis by race/ethnicity, weight and HCV genotype. Hepatology2008; 48Suppl 1: 1160A.
48.
JensenD., WedemeyerH., HerringR.High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa-2a (40KD)/RBV: planned week 12 interim analysis from the PROPEL study. Hepatology2010; 52Suppl 1: 360A.
49.
PockrosP., JensenD., TsaiN.First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis from the JUMP-C trial. J Hepatol2011; 54Suppl 1: S538.
50.
GaneE.J., RobertsS.K., StedmanC.A.Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet2010; 376: 1467–1475.
51.
Le PogamS., ChhabraM., YanJ-M. Low rate of viral load rebound observed among treatment-naive genotype 1 patients with chronic hepatitis C treated with danoprevir (RG7227) plus PEG-IFN alfa-2a (40KD) (PEGASYS) plus ribavirin: interim analysis. Hepatology2010; 52Suppl 1: 703A–704A.
52.
Le PogamS., SeshaaddriA., KosakaA.No evidence of drug resistance after up to 4 weeks treatment of GT 1, 2 and 3 hepatitis C virus infected individuals. J Hepatol2009; 50Suppl 1: S348.
53.
Le PogamS., SeshaadriA., EwingA.RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J Infect Dis2010; 202: 1510–1519.
54.
MargeridonS., Le PogamS., LiuT.Ultra-deep sequencing of the NS3 and NS5B regions detects preexisting resistant variants to direct acting antivirals (DAA) in HCV genotype 1 treatment-naive infected patients. Hepatology2010; 52Suppl 1: 714A.
55.
KuntzenT., TimmJ., BericalA.Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology2008; 48: 1769–1778.
56.
GaudieriS., RauchA., PfafferottK.Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology2009; 49: 1069–1082.
57.
TreviñoA., de MendozaC., ParraP.Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients. Antivir Ther2011; 16: 413–416.
58.
Le PogamS., YanJ-M, KosakaA.No evidence of drug resistance or baseline S282T resistance mutation among GT1 and GT4 HCV-infected patients on nucleoside polymerase inhibitor RG7128 and PEG-IFN/RBV combination treatment for up to 12 weeks: interim analysis from the PROPEL study. Hepatology2010; 52Suppl 1: 701A–702A.
59.
Clinicaltrials.gov.A study on the combination of RO5024048 and ritonavir-boosted danoprevir with and without Copegus (ribavirin) in interferon-naive patients with chronic hepatitis C genotype 1 (INFORM-SVR). Clinicaltrials.gov NCT01278134. (Accessed 27 July 2011.) Available from http://clinicaltrials.gov/ct2/show/NCT01278134?term=danoprevir&rank=3.
60.
Clinicaltrials.gov.A study of danoprevir/ritonavir and Copegus with RO5024048 and/or Pegasys in patients with chronic hepatitis C. Clinicaltrials.gov NCT01331850. (Accessed 31 July 2011.) Available from http://clinicaltrials.gov/ct2/show/NCT01331850?term=RO5024048&rank=2.
61.
SarrazinC., LimS., QiX.Kinetic analysis of viral rebound and drug-resistant viral variant dynamics in patients treated with ITMN-191 (RG7227) monotherapy suggests a high barrier to viral escape. Hepatology2009; 50Suppl 1: 953A.
62.
SchlütterJ.Therapeutics: new drugs hit the target. Nature2011; 474: S5–7.
